Abstract
Introduction

Deregulation of cell cycle progression and differentiation contributes to the malignant transformation. Growth factors such as neuropeptide growth hormone releasing hormone (GHRH) are involved in the maintenance of these phenomena, as was recently shown by the knocking down of this hormone in breast, prostate and lung cancer cell lines
. When the tumoral mitogenic signals of GHRH were disrupted by specifically designed siRNA, the growth of these cancers was rapidly suppressed. In an endeavour to develop new anticancer agents, one of us (A.V.S.) synthesized GHRH antagonists [2] . These compounds can antagonize the mitogenic effects of GHRH in cancers, and thus possess strong anticancer activity in diverse tumours [3] . The action of GHRH antagonists is mediated through the pituitary GHRH receptor, as well as its splice variant 1 (SV1), which can exert a ligand independent activity [4, 5] .
Recent study showed that GHRH and GHRH antagonists can influence the reduction/oxidation (redox) status of LNCaP cancer cells [6] . GHRH increased the production of the reactive oxygen species (ROS) and enhanced the lipid and protein oxidation levels of these cells. In contrast, GHRH antagonists showed anti-oxidative activity and decreased the oxidation levels of these cells [6] . The ability of these compounds to reduce the metabolism of the ROS is of major importance, because these species are strongly involved in the initiation, promotion and progression of cancers [7, 8] . Another oxidant species is the peroxynitrite, which results from the reaction of nitric oxide and superoxide [9] . The chemistry of nitric oxide and the related nitrogen oxygen species as well as their endogenously production adds a new dimension to redox pathology and pathophysiology and increases the complexity of the understanding of free radical biology [10] .
Nitric oxide and nitric oxide derived reactive nitrogen species are an essential part of the immunoresponse and physiological signal transduction pathways [11] [12] [13] . They are also involved in the pathogenesis of a broad variety of diseases [14] [15] [16] [17] [18] [19] through the induction of oxidative and nitrosative stress [10, [20] [21] [22] . Nitric oxide is produced by the family of the nitric oxide synthases. Inducible nitric oxide synthase (iNOS) is one of the three isoforms of nitric oxide synthase, which catalyses the oxidative deamination of L-arginine to produce citrulline and nitric oxide [23] .
The iNOS expression in tumour cells is associated with cell proliferation and enhancement of cancer migration and invasion [24] . The importance of the nitric oxide expression in the pathogenesis of various diseases including cancer is underlined by the fact that various nitric oxide inhibitors have been developed [20] in order to modulate the intracellular levels of this molecule [25] .
The influence of GHRH and its antagonists on the expression of the iNOS, which is strongly involved in tumour progression [16, 24, 26] 
Material and methods
Peptides and chemicals
GHRH 
Quantitative analysis of the immunoblot assay
The protein band signals were quantified by Adobe Photoshop and normalized to ␤-actin signal. In the case of the ERK1/2 and NFBp50 activation, the bands were normalized to ERK2 and NF-B50, respectively. The intensity of the bands was equal to their mean value multiplied by their pixel value (absolute intensity). Relative intensity (R.I.) of each band was calculated by dividing its absolute intensity by the absolute intensity of the control band (␤-actin, ERK2 or NFBp50).
Statistical analysis
The data are expressed as the mean Ϯ S.E. Statistical evaluation of the results was performed with a one way ANOVA followed by the least significant difference test. The differences were considered significant at P Ͻ 0.05.
Results
Expression of GHRH Receptors and GHRH in A549 human lung cancer cell line
The expression of GHRH receptors was examined by Western blot in A549 human lung cancer cells, using 3T3 mouse fibroblast line as a negative [4, 27] and LNCaP as a positive control [1] . The antibody used recognized both type of GHRH receptors (pGHRHR and SV1). Figure 1B also shows the lack of GHRH-R(s) expression in 3T3 cells. T47D cells which express both types of GHRH receptors [1, 28] were used as positive control. In addition, we detected the expression of the GHRH in A549 cells, using LNCaP and T47D cancer cells as positive controls [1] . The results are shown in Figure 1C .
Activation of the ERK1/2 pathway by GHRH in A549 lung cancer cells
We investigated whether GHRH Figure 3A .
The proliferation of the 3T3 cells, which do not express GHRH receptors, was not influenced by GHRH, MZ-1-156 or the ERK inhibitor.
The results are shown in Figure 3B . 
Fig. 1 (A) Western blot analysis of the expression of GHRH receptor(s) in A549 lung cancer, LNCaP prostate cancer cell line and 3T3 mouse fibroblast cell line. LNCaP and 3T3 cells were used as positive and negative controls, respectively. (B) Western blot analysis of the expression of GHRH receptor(s) in T47D breast cancer cells and 3T3 mouse fibroblast cell line. T47D cells were used as positive control. (C) Western blot analysis of the expression of GHRH in LNCaP, A549 and T47D cancer cell lines. LNCaP and T47D cells were used as positive controls.
Fig. 2 Western blot analysis of the pERK1/2 after incubation of the A549 cells with GHRH antagonist MZ-5-156 and GHRH. The protein levels were normalized to ERK2 signal (loading control). The blot is representative of two independent experiments.
Expression of proliferating cell nuclear antigen in A549 and 3T3 cells after treatment with GHRH or GHRH antagonist
A549 cancer cells cultured in vitro were exposed to two concentrations of GHRH and GHRH antagonist MZ-5-156. GHRH
Expression of wild-type P53 in A549 cells after treatment with GHRH or GHRH antagonist
The expression of the wild-type P53 was measured in the A549 lung cancer cells after exposure to 0.1 M and 1 M GHRH or higher in the cells exposed to the GHRH (R.I.: 1.54, 3.63 ) and lower to the cells exposed to [31] . GHRH antagonists can counteract these effects.
Effect of GHRH (1-29)NH 2 and GHRH antagonist MZ-5-156 on the expression on iNOS in A549 lung cancer cells in vitro
A549 lung cancer cells cultured in vitro were exposed to GHRH and GHRH antagonist MZ-5-156 and the expression levels of iNOS were detected by Western blot. iNOS protein expression was lower
In addition to the endocrine related pathways, GHRH can also increase the redox status of the LNCaP prostate cancer cell lines through an increase in the metabolism of the ROS [6] . These species have been shown to influence various human diseases and malignancies [32] [33] [34] [35] . The reactive nitrogen species can also contribute to protein and lipid modifications as well as deregulate intracellular signalling pathways [36, 37] . The influence of GHRH on the expression of iNOS has not been investigated before.
In [39, 40] . In vivo studies showed a reduced expression of PCNA and iNOS in animal models after anti-oxidant therapy [41] . [6] . It has been previously demonstrated that a balance between p53 and MAPK pathways is critical for preventing or promoting initiation of tumours [42] and that P53 can trigger strong antioxidative intracellular mechanisms [43, 44] , which involve a downregulation of inducible nitric oxide and cyclooxygenase 2 [45] .
The expression of the iNOS was strongly increased by GHRH in the A549 cells, whereas GHRH antagonist MZ-5-156 reduced it. The activation of ERK1/2, which occurred upon the binding of GHRH to its receptors [30] , has been previously shown to increase the expression of the iNOS [46] [47] [48] [49] [50] and nitric oxide [12, 21] . GHRH did not influence the expression of iNOS in 3T3 cells, which do not respond to GHRH or its antagonists.
GHRH also stimulated the NF-B transcription factor, which is not only known to activate angiogenic factors [51] but also the expression of genes involved in encoding enzymes in the prostaglandin-synthesis pathway such as COX-2 and the iNOS [52] . A direct up-regulation of iNOS by COX-2 has also been proposed [53] as well as a model of direct interaction among these proteins [54] . In addition the activation of NF-B induces the iNOS expression [23, [55] [56] [57] .
Previous studies have demonstrated the role of nitric oxide in tumour promotion and progression by mediating critical processes, including angiogenesis, tumour cell growth and invasion [21] . Our study shows for the first time that GHRH can activate the iNOS expression and that GHRH antagonists inhibit it; thus GHRH antagonist might be useful for the treatment of diseases related to increased oxidative and nitrosative stress.
